Literature DB >> 11504798

Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation.

P A Zaki1, D E Keith, J B Thomas, F I Carroll, C J Evans.   

Abstract

In this study, we explored the relationship between ligand-induced regulation of surface delta opioid receptors and G protein activation. G protein activation was assessed with [(35)S]guanosine-5'-O-(3-thio)triphosphate (GTP gamma S) binding assays conducted at both 37 and 0 degrees C. Ligand-independent (constitutive) activity of the delta-receptor was readily observed when the [(35)S]GTP gamma S binding assay was performed at 37 degrees C. We identified a new class of alkaloid inverse agonists (RTI-5989-1, RTI-5989-23, RTI-5989-25), which are more potent than the previously described peptide inverse agonist ICI-174864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu). Treatment with these inverse agonists for 18 h caused up-regulation of surface receptors. Eighteen-hour treatment with etorphine resulted in approximately 90% loss of surface receptor, whereas fentanyl, diprenorphine, and morphine caused between 20 and 50% loss. The abilities of ligands to modulate [(35)S]GTP gamma S binding at 37 degrees C showed a strong correlation with their abilities to regulate surface receptor number (r(2) = 0.86). Interestingly, the ability of fentanyl to activate G proteins was markedly temperature sensitive. Fentanyl showed no stimulation of [(35)S]GTP gamma S binding at 0 degrees C but was as efficacious as etorphine, morphine, and diprenorphine at 37 degrees C. Neither the ligand-induced receptor increases nor decreases were perturbed by pertussis toxin pretreatment, suggesting that functional G proteins are not required for ligand-regulated delta-opioid receptor trafficking.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504798

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

Review 2.  The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.

Authors:  F Ivy Carroll; Roland E Dolle
Journal:  ChemMedChem       Date:  2014-06-30       Impact factor: 3.466

3.  Delta opioid receptor ligands modulate anxiety-like behaviors in the rat.

Authors:  Shane A Perrine; Brian A Hoshaw; Ellen M Unterwald
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

4.  Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Authors:  M F Divin; F A Bradbury; F I Carroll; J R Traynor
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

5.  G protein independent phosphorylation and internalization of the delta-opioid receptor.

Authors:  Faye A Bradbury; Jennifer C Zelnik; John R Traynor
Journal:  J Neurochem       Date:  2009-04-01       Impact factor: 5.372

6.  Functional characterization of human variants of the mu-opioid receptor gene.

Authors:  Ajay Ravindranathan; Geoff Joslyn; Margaret Robertson; Marc A Schuckit; Jennifer L Whistler; Raymond L White
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-15       Impact factor: 11.205

7.  Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase.

Authors:  Erica S Levitt; Mary J Clark; Paul M Jenkins; Jeffrey R Martens; John R Traynor
Journal:  J Biol Chem       Date:  2009-06-11       Impact factor: 5.157

8.  Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists.

Authors:  Parthasaradhireddy Tanguturi; Vibha Pathak; Sixue Zhang; Omar Moukha-Chafiq; Corinne E Augelli-Szafran; John M Streicher
Journal:  Molecules       Date:  2021-11-05       Impact factor: 4.927

9.  Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.

Authors:  Karl Brillet; Brigitte L Kieffer; Dominique Massotte
Journal:  BMC Pharmacol       Date:  2003-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.